If You Invested in Filana Therapeutics (FLNA)

Filana Therapeutics, Inc. develops investigational biotechnology therapies focused on Tuberous Sclerosis Complex-related epilepsy. The company’s lead program centers on simufilam, a proprietary oral small molecule intended to modulate the filamin A protein. Filana Therapeutics trades on the Nasdaq Capital Market under the symbol FLNA and is headquartered in Austin, Texas.

The company’s current scientific focus is the relationship between filamin A biology and central nervous system disorders, including TSC-related epilepsy. Tuberous Sclerosis Complex is associated with neurological manifestations that can include epilepsy, and Filana Therapeutics is evaluating simufilam as a potential treatment approach within that disease context. The company has also described its broader interest in diseases associated with dysregulation or overexpression of filamin A.

Filana Therapeutics is a development-stage biotechnology company rather than a commercial drug manufacturer. Its business model is based on research and development, preclinical work, regulatory engagement, and clinical-development planning for investigational medicines. Company updates have described preclinical data for simufilam in a mouse model of severe TSC-related epilepsy, scientific presentations on the biological rationale for the program, and work related to regulatory requirements for advancing the program.

Program and technology focus

Simufilam is described by the company as an oral small molecule intended to modulate filamin A protein. The program is directed primarily toward TSC-related epilepsy, a central nervous system disorder area. Filana Therapeutics has reported preclinical findings in this indication and has presented scientific rationale for evaluating simufilam in TSC-related epilepsy.

The company’s development activities include preclinical studies, protocol design work, and regulatory interactions with the U.S. Food and Drug Administration. Its TSC-related epilepsy program has been subject to an FDA clinical hold, and company materials describe efforts to generate additional data and address regulator feedback. These activities place the company within the clinical-stage biotechnology category, where operating results are driven by research spending, development timelines, regulatory status, and financing resources rather than product revenue from approved therapies.

Corporate identity

Filana Therapeutics was formerly known as Cassava Sciences, Inc. The company announced its name change and new ticker symbol in 2026, aligning the corporate identity with its focus on filamin A modulation and TSC-related epilepsy. The FLNA ticker represents the renamed public company and its continuing biotechnology development activities.

As a public biotechnology issuer, Filana Therapeutics’ disclosures commonly address research progress, financial results, regulatory matters, corporate governance, compensation, board composition, and the risks inherent in drug discovery and development. Its operating profile is concentrated, with company-specific attention centered on simufilam, filamin A modulation, TSC-related epilepsy, and the regulatory path for investigational therapy development.